Oracle Investment Management Inc Mirati Therapeutics, Inc. Transaction History

Oracle Investment Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$36.13 - $49.49 $1.76 Million - $2.42 Million	-48,800 Reduced 24.23%	152,600 $5.51 Million
Q1 2023 May 15, 2023	BUY	$36.54 - $54.26 $4.78 Million - $7.11 Million	130,947 Added 185.86%	201,400 $7.49 Million
Q4 2022 Feb 14, 2023	SELL	$41.27 - $98.62 $9.71 Million - $23.2 Million	-235,176 Reduced 76.95%	70,453 $3.19 Million
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $7.77 Million - $11.3 Million	130,629 Added 74.65%	305,629 $21.3 Million
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $6.85 Million - $15.5 Million	175,000 New	175,000 $11.7 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Oracle Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Oracle Investment Management Inc with notifications on news.